![Biotech Stocks Facing FDA Decision In December 2022]( "fda-oct24.jpg")
Now, let’s take a look at the biotech stocks facing FDA decision in December.
![Biotech Stocks Facing FDA Decision In November 2022]( "fda-oct26.jpg")
The FDA has approved 28 novel drugs so far this year, including 2 in October
![Biotech Stocks Facing FDA Decision In October 2022]( "fda-may25.jpg")
The FDA has approved only 24 novel drugs this year (Jan. to Sep.) compared to 40 during the same period last year.
![Biotech Stocks Facing FDA Decision In September]( "fda-aug26.jpg")
The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. This one-time gene therapy by the name Zynteglo, developed by bluebird bio Inc. (BLUE), reportedly carries a price tag of $2.8 million.
![Biotech Stocks Facing FDA Decision In June 2022]( "collage-0526.jpg")
As another month comes to a close, it’s time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what’s in store on the regulatory front in June.
![Biotech Stocks Facing FDA Decision In March 2022]( "fda-feb25.jpg")
As another month comes to an end, it’s time to take a look back at some of the regulatory news that made headlines in February and look ahead to what the month of March has in store.
![Biotech Stocks Facing FDA Decision In February 2022]( "fda-jan25.jpg")
As we head into February, it's time to take a look back at some of the regulatory news that made headlines in January.
![Biotech Stocks Facing FDA Decision In January 2022]( "fda-dec27.jpg")
As another month comes to an end, we take a look back at some of the regulatory news that dominated the headlines and look ahead to what’s in store for January.